Biocartis Group NV (LTS:0R72) EBIT per Share: €-0.71 (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R72 Biocartis Group NV LTS:0R72
14 GF Score
Price €0.30
View Full Analysis

What is Biocartis Group NV EBIT per Share?

Biocartis Group NV LTS:0R72 14 EBIT per Share is €-0.71 as of Jun. 2023. GuruFocus rates LTS:0R72 with a GF Score™ of 14/100.

Biocartis Group NV's EBIT per Share for the six months ended in Jun. 2023 was €-0.23. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.71.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biocartis Group NV's EBIT per Share or its related term are showing as below:

LTS:0R72's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13.1
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Biocartis Group NV's EBIT for the six months ended in Jun. 2023 was €-21.64 Mil.

Biocartis Group NV  (LTS:0R72) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biocartis Group NV EBIT per Share Related Terms

Biocartis Group NV EBIT per Share Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV EBIT per Share Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -0.87 -0.80 -1.08 -0.90

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.62 -0.42 -0.48 -0.23
LTS:0R72
14GF Score
Biocartis Group NV LTS:0R72
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biocartis Group NV's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-54.434/60.546
=-0.90

Biocartis Group NV's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

EBIT per Share(Q: Jun. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-21.641/93.231
=-0.23

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of €-0.71 mean?
Biocartis Group NV (LTS:0R72) has a EBIT per Share of €-0.71 as of Jun. 2023. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biocartis Group NV and its competitors.
Is Biocartis Group NV's EBIT per Share too high?
Biocartis Group NV's current EBIT per Share is €-0.71. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's EBIT per Share compare to TMO and DHR?
Biocartis Group NV's EBIT per Share of €-0.71 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biocartis Group NV and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocartis Group NV's current EBIT per Share is €-0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current EBIT per Share of €-0.71. The current EBIT per Share is €-0.71. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current EBIT per Share is €-0.71 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for LTS:0R72

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price